Clinical Trial Detail

NCT ID NCT02871843
Title Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors EpicentRx, Inc.
Indications

gliosarcoma

malignant glioma

glioblastoma multiforme

Therapies

RRx-001 + Temozolomide

Age Groups: adult senior

No variant requirements are available.